Sustained Complete Response after Maintenance Therapy with Topotecan and Erlotinib for Recurrent Cervical Cancer with Distant Metastases

INTRODUCTION: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this se...

Descripción completa

Detalles Bibliográficos
Autores principales: Callegaro-Filho, Donato, Kavanagh, John J., Nick, Alpa M., Ramirez, Pedro T., Schmeler, Kathleen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: January, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934679/
https://www.ncbi.nlm.nih.gov/pubmed/24575024
http://dx.doi.org/10.1159/000358916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934679/
https://www.ncbi.nlm.nih.gov/pubmed/24575024
http://dx.doi.org/10.1159/000358916

Ejemplares similares